非小細胞肺がん治療薬の世界市場：2025年～2033年

非小細胞肺がん治療薬の世界市場は、2024年に213億3,000万米ドルに達し、2033年までには649億2,000万米ドルに達すると予測され、予測期間中の2025年から2033年にはCAGR11.75％で成長すると予測されています。

非小細胞肺がん（NSCLC）は、すべての肺がん症例の中で最も有病率の高い肺がんです。NSCLCには、主に腺がん、扁平上皮がん、大細胞がんといったさまざまな亜型があります。最も一般的な亜型である腺がんは、しばしば肺の外側の領域に発生し、非喫煙者にも発生する可能性があります。

NSCLCの治療には、病期と特徴に合わせたいくつかの治療選択肢があります。切除不能な患者に対しては、局所病変をコントロールするために放射線療法が採用されます。化学療法は進行した病期に対する基本であり、しばしばネオアジュバント療法またはアジュバント療法として手術と併用されます。

最近の進歩により、腫瘍細胞内の特定の遺伝子変異に焦点を当てた分子標的治療が出現し、より個別化された治療選択肢が提供されるようになりました。さらに免疫療法は、がん細胞と闘うために身体の免疫系を利用することでNSCLC治療に革命をもたらし、多くの患者に大きな生存利益をもたらしています。

市場力学：

促進要因と抑制要因

研究開発の進展

研究開発の進展は、技術革新を促進し治療効果を高めることで、非小細胞肺がん（NSCLC）治療薬市場を大きく牽引すると期待されます。研究開発への継続的な投資により、特に標的療法や免疫療法などの新規療法が開発され、患者の予後改善に有望な結果を示しています。

さらに、がん生物学の研究が進むにつれて、複数の作用機序を活用した併用療法の設計が容易になり、治療効果がさらに向上しています。例えば、2022年12月、GSK plcは転移性非扁平上皮非小細胞肺がん（NSCLC）患者に対する一次治療として、ドスターリマブと化学療法の併用とペムブロリズマブと化学療法の併用を検討したPERLA第II相臨床試験の結果を発表しました。

新薬のパイプラインの増加と個別化医療アプローチの出現も、患者固有の遺伝子プロファイルに対応するため、市場拡大に寄与しています。先進的研究による革新的ソリューションの開発も市場拡大に寄与しています。例えば、2024年12月、Datopotamab deruxtecan（Dato-DXd）は、EGFRチロシンキナーゼ阻害薬（TKI）およびプラチナ製剤ベースの化学療法による治療中または治療後に病勢進行した局所進行性または転移性の上皮成長因子受容体変異（EGFRm）非小細胞肺がん（NSCLC）成人患者の治療薬として、米国で画期的治療薬指定（BTD）を取得しました。

さらに、がん研究に対する政府および民間部門からの資金提供の増加が技術革新を促進し、効果的なNSCLC治療に対する需要の高まりに対応することが期待される先進的な治療オプションの導入につながっています。その結果、こうした進歩は治療へのアクセスを向上させ、全生存率を改善する可能性が高く、NSCLC治療薬市場の成長を後押ししています。

高い治療費

非小細胞肺がん（NSCLC）の治療には高い費用がかかるため、非小細胞肺がん治療薬市場の成長は大きく阻害されると予想されます。この経済的負担は、特に低・中所得者層において、しばしば治療アドヒアランスの低下、あるいは治療を完全に放棄する選択肢をもたらします。

さらに、新薬間の価格競争がないため、患者の転帰が改善されないまま価格が上昇し続け、状況を悪化させています。その結果、こうした経済的な問題は個々の患者に影響を及ぼすだけでなく、ヘルスケアシステムにも圧力をかけ、新薬開発への投資を減少させ、市場開拓を制限することになりかねません。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 研究開発の進歩
  • 抑制要因
    • 治療費の高騰
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 タイプ別

• 腺がん
• 扁平上皮がん
• 大細胞がん
• 腺扁平上皮がん
• 肉腫様がん

第7章 治療別

• 放射線治療
• 化学療法
• 標的療法
• 免疫療法
• レーザー治療
• 光線力学療法（PDT）
• その他

第8章 エンドユーザー別

• 病院
• がんセンター
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• F. Hoffmann-La Roche Ltd
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 過去および予測の製品販売
    • 製品販売量
  • 財務概要
    • 会社の収益
    • 地域別収益分配
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Novartis AG
• Bayer AG
• Eli Lilly and Company
• Merck & Co., Inc.
• AstraZeneca
• Johnson & Johnson Services, Inc.
• Processa Pharmaceuticals, Inc
  • パイプライン製品の説明
  • 製品の主要業績評価指標（KPI）
  • 主な活動
  • 市場参入のタイムライン
  • 製品普及率
  • 売上予測と予測
• Vanda Pharmaceuticals Inc.
• Renexxion Ireland Limited
• Aclipse Therapeutics
• 各市場参入企業に対しても同様のデータが提供されます。

第12章 付録

The global non-small cell lung cancer therapeutics market reached US$ 21.33 billion in 2024 and is expected to reach US$ 64.92 billion by 2033, growing at a CAGR of 11.75% during the forecast period 2025-2033.

Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer of all lung cancer cases. It encompasses various subtypes, primarily adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Adenocarcinoma, the most common subtype, often arises in the outer regions of the lungs and can occur in non-smokers.

The treatment landscape for NSCLC includes several therapeutic options tailored to the disease's stage and characteristics. For patients with unresectable disease, radiation therapy may be employed to control local disease. Chemotherapy remains a cornerstone for advanced stages, often used in conjunction with surgery as neoadjuvant or adjuvant therapy.

Recent advancements have led to the emergence of targeted therapies that focus on specific genetic mutations within tumor cells, providing more personalized treatment options. Additionally, immunotherapy has revolutionized NSCLC treatment by harnessing the body's immune system to fight cancer cells, offering significant survival benefits for many patients.

Market Dynamics: Drivers & Restraints

Advancements in Research and Development

Advancements in research and development are expected to significantly drive the non-small cell lung cancer (NSCLC) therapeutics market by fostering innovation and enhancing treatment efficacy. Continuous investment in R&D has led to the development of novel therapies, particularly in targeted therapy and immunotherapy, which have shown promising results in improving patient outcomes.

Additionally, the increasing studies of cancer biology have facilitated the design of combination therapies that leverage multiple mechanisms of action, further improving therapeutic efficacy. For instance, in December 2022, GSK plc announced results from the PERLA phase II clinical trial investigating dostarlimab in combination with chemotherapy versus pembrolizumab in combination with chemotherapy as a first-line treatment for patients with metastatic non-squamous non-small cell lung cancer (NSCLC).

The growing pipeline of new drugs and the emergence of personalized medicine approaches are also contributing to market expansion, as they cater to the unique genetic profiles of patients. The development of innovative solutions with advanced research is contributing to the market growth. For instance, in December 2024, Datopotamab deruxtecan (Dato-DXd) was granted Breakthrough Therapy Designation (BTD) in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with disease progression on or after treatment with an EGFR-tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.

Furthermore, increased funding from both the government and private sectors for cancer research is promoting innovation, leading to the introduction of advanced treatment options that are expected to meet the rising demand for effective NSCLC therapies. As a result, these advancements are likely to enhance treatment accessibility and improve overall survival rates, thereby propelling growth in the NSCLC therapeutics market.

High Costs of Treatment

The high costs of treating non-small cell lung cancer (NSCLC) are expected to impede the growth of the non-small cell lung cancer therapeutics market significantly. This financial burden often results in lower treatment adherence or even the choice to skip therapy entirely, especially among low- and middle-income populations.

Additionally, the absence of price competition among new drugs worsens the situation, as prices keep increasing without any corresponding improvements in patient outcomes. As a result, these affordability issues affect individual patients and put pressure on healthcare systems, which could lead to decreased investment in new drug development and restrict market growth.

Segment Analysis

The global non-small cell lung cancer therapeutics market is segmented based on type, treatment, end-user, and region.

Treatment:

Targeted therapy segment is expected to dominate the global non-small cell lung cancer therapeutics market share

Targeted therapy segment is expected to dominate the non-small cell lung cancer therapeutics market. This dominance is attributed to several factors. Targeted therapies specifically address genetic mutations and molecular pathways involved in cancer growth, which can lead to improved patient outcomes and fewer side effects compared to traditional chemotherapy.

Additionally, advancements in research and the development of new targeted agents continue to enhance their effectiveness, making them a preferred choice for treating advanced NSCLC. Companies are developing advanced targeted therapies. For instance, in February 2024, Bayer announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for BAY 2927088, a targetted drug intended for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) harboring activating HER2 (ERBB2) mutations who have previously received systemic therapy.

While chemotherapy remains widely used, especially in developing regions, the trend is shifting towards more personalized and effective treatment modalities like targeted therapy, which is expected to drive further growth in the NSCLC therapeutics market.

Geographical Analysis

North America is expected to hold a significant position in the global non-small cell lung cancer therapeutics market share

North America is expected to dominate the non-small cell lung cancer (NSCLC) therapeutics market due to several key factors. The dominance is driven by a robust healthcare infrastructure, advanced medical technologies, and the presence of major pharmaceutical companies actively developing innovative therapies. The companies are receiving approvals for their innovative solutions which are contributing to the market growth. For instance, In August 2024, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) granted approval for its combination treatment of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) as a first-line therapy for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) exhibiting epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as identified by an FDA-approved test.

Companies in the region are increasingly investing in developing innovative therapeutics to address the disease. For instance, in March 2024, Merck announced that the Phase 3 KEYLYNK-006 trial assessing KEYTRUDA, Merck's anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, did not achieve its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of certain patients with metastatic non-squamous non-small cell lung cancer (NSCLC).

Increased awareness regarding early diagnosis and treatment options has further contributed to market growth, as more patients seek timely interventions. The U.S. specifically plays a pivotal role in this landscape due to high smoking rates and air pollution contributing to lung cancer prevalence. With ongoing investments in research and development, North America is poised to maintain its leadership position in the NSCLC therapeutics market for the foreseeable future.

Competitive Landscape

The major global players in the non-small cell lung cancer therapeutics market include F. Hoffmann-La Roche Ltd, Mylan N.V., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., AstraZeneca and Johnson & Johnson Services, Inc. among others.

Key Developments

• In August 2024, AstraZeneca's Imfinzi (durvalumab) received approval in the United States for use in combination with chemotherapy to treat adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) who do not have known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
• In October 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI (encorafenib) in combination with MEKTOVI (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have a BRAF V600E mutation, as identified by an FDA-approved test. This approval provides a new personalized treatment option for patients with this specific mutation in their cancer.
• In August 2023, Eli Lilly and Company announced the topline results from the LIBRETTO-431 study, which evaluated Retevmo (selpercatinib) against platinum-based chemotherapy plus pemetrexed as an initial treatment for patients with rearranged during transfection (RET) fusion-positive advanced or metastatic non-small cell lung cancer (NSCLC).

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Non-Small Cell Lung Cancer Therapeutics Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Advancements in Research and Development
  • 4.1.2. Restraints
    • 4.1.2.1. High Costs of Treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Adenocarcinoma*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Squamous Cell Carcinoma
• 6.4. Large Cell Carcinoma
• 6.5. Adenosquamous Carcinoma
• 6.6. Sarcomatoid Carcinoma

7. By Treatment

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 7.1.2. Market Attractiveness Index, By Treatment
• 7.2. Radiation Therapy*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Chemotherapy
• 7.4. Targeted Therapy
• 7.5. Immunotherapy
• 7.6. Laser Therapy
• 7.7. Photodynamic Therapy (PDT)
• 7.8. Others

8. By End-User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.1.2. Market Attractiveness Index, By End-User
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Cancer Centers
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

Key Market Players

• 11.1. F. Hoffmann-La Roche Ltd*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio
    • 11.1.2.1. Product Description
    • 11.1.2.2. Product Key Performance Indicators (KPIs)
    • 11.1.2.3. Historic and Forecasted Product Sales
    • 11.1.2.4. Product Sales Volume
  • 11.1.3. Financial Overview
    • 11.1.3.1. Company Revenue's
    • 11.1.3.2. Geographical Revenue Shares
    • 11.1.3.3. Revenue Forecasts
  • 11.1.4. Key Developments
    • 11.1.4.1. Mergers & Acquisitions
    • 11.1.4.2. Key Product Development Activities
    • 11.1.4.3. Regulatory Approvals etc.
  • 11.1.5. SWOT Analysis
• 11.2. Mylan N.V.
• 11.3. Teva Pharmaceutical Industries Ltd.
• 11.4. Pfizer Inc.
• 11.5. Novartis AG
• 11.6. Bayer AG
• 11.7. Eli Lilly and Company
• 11.8. Merck & Co., Inc.
• 11.9. AstraZeneca
• 11.10. Johnson & Johnson Services, Inc.
• Similar data will be provided for each market player.

Emerging Market Players

• 11.11. Processa Pharmaceuticals, Inc.*
  • 11.11.1. Pipeline Products Description
  • 11.11.2. Product Key Performance Indicators (KPIs)
  • 11.11.3. Key Activities
  • 11.11.4. Market Entry Timelines
  • 11.11.5. Product Penetration Rate
  • 11.11.6. Sales Estimation and Projections
• 11.12. Vanda Pharmaceuticals Inc.
• 11.13. Renexxion Ireland Limited
• 11.14. Aclipse Therapeutics
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us